Cognitive, neuropsychiatric and neurological alterations in mastocytosis: A systematic review [PDF]
Clinical and Translational Allergy, 2023 Background Mastocytosis manifests with multisystemic symptoms, often involving the nervous system. Numerous cognitive, neuropsychiatric and neurological alterations have been reported in multiple observational studies.
Elena Sagües‐Sesé +2 more
doaj +3 more sources
Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features [PDF]
Clinical and Translational Allergy, 2022 Background Nonsteroidal anti‐inflammatory drugs (NSAIDs) are frequently avoided in mastocytosis, because of a potential increased risk for drug hypersensitivity reactions (DHRs) due to inhibition of cyclo‐oxygenase (COX), subsequent depletion of ...
Tiago Azenha Rama +9 more
doaj +3 more sources
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal [PDF]
HemaSphere, 2021 Mastocytosis is a hematologic neoplasm characterized by expansion and focal accumulation of neoplastic mast cells (MC) in diverse organs, including the skin, bone marrow (BM), spleen, liver, and gastrointestinal tract.
Peter Valent +39 more
doaj +3 more sources
Altered innate immune profile in blood of systemic mastocytosis patients. [PDF]
Clin Transl Allergy, 2022 Abstract Background Mast cells (MC) from systemic mastocytosis (SM) patients release MC mediators that lead to an altered microenvironment with potential consequences on innate immune cells, such as monocytes and dendritic cells (DC). Here we investigated the distribution and functional behaviour of different populations of blood monocytes and DC among
Pérez-Pons A +16 more
europepmc +2 more sources
Markedly Increased Diamine Oxidase During Acute Anaphylaxis Is Associated With an Underlying Clonal Mast Cell Disorder. [PDF]
Clin Exp AllergyWe provide the first evidence that pronounced release of DAO during anaphylaxis is restricted to patients with clonal mast cell disorder. This finding offers possible functional support for the reported association between KIT p.D816V and anaphylaxis severity.
Rijavec M +5 more
europepmc +2 more sources
Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap [PDF]
Frontiers in Pharmacology, 2020 Systemic mastocytosis is a rare and heterogeneous disease characterized by mast cell proliferation and activation. KIT is a transmembrane tyrosine kinase which plays a key role in mast cell growth, differentiation and survival. After interaction with its
Miguel Piris-Villaespesa +1 more
doaj +2 more sources
Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas [PDF]
Frontiers in Oncology, 2021 Human WHO grade 1 meningiomas are generally considered benign tumors; despite this, they account for ≈50% of all recurrent meningiomas. Currently, limited data exist about the mutational profiles of grade 1 meningiomas and patient outcome.
María González-Tablas +28 more
doaj +2 more sources
Mastocitosis cutánea maculopapular infantil: reporte de un caso
Revista Médica Clínica Las Condes, 2019 Resumen: Objetivo: Reportar un caso de mastocitosis cutánea maculopapular de inicio en la infancia y realizar una revisión bibliográfica con énfasis en el diagnóstico, estudio, pronóstico y tratamiento.
Alvaro Ibarra, Ivo Sazunic
exaly +3 more sources
Insights in Anaphylaxis and Clonal Mast Cell Disorders [PDF]
Frontiers in Immunology, 2017 The prevalence of anaphylaxis among patients with clonal mast cell disorders (MCD) is clearly higher comparing to the general population. Due to a lower frequency of symptoms outside of acute episodes, clonal MCD in the absence of skin lesions might ...
David González-de-Olano +1 more
doaj +2 more sources
High burden of clonal mast cell disorders and hereditary α-tryptasemia in patients who need Hymenoptera venom immunotherapy. [PDF]
AllergyIn this multicenter study, we have demonstrated that clonal mast cell disease and HαT are more prevalent among individuals who need VIT; one or both was found in 27% of individuals overall. Both diagnoses were highly concentrated among individuals with severe anaphylaxis.
Korošec P +24 more
europepmc +2 more sources